Genmab A (GMAB) Change in Accured Expenses (2019 - 2026)

Genmab A has reported Change in Accured Expenses for 6 years, with the latest figure at $861.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 1971.74% year-over-year to $861.0 million; the trailing twelve-month figure through Mar 2026 stood at $861.0 million (up 223.68% YoY), and the FY2025 full-year result was $1.1 billion, up 118.61% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $861.0 million, down from $1.1 billion in the prior quarter.
• The five-year high for Change in Accured Expenses was $1.1 billion in Q4 2025, with the low at -$46.0 million in Q1 2025.
• Historically, Change in Accured Expenses has averaged $292.1 million across 4 years, with a median of $99.5 million in 2023.
• Annual changes were most pronounced in 2025 — Change in Accured Expenses tumbled 258.62% — and 2026, when it surged 1971.74%.
• Genmab A's Change in Accured Expenses stood at $90.0 million in 2023, then soared by 35.56% to $122.0 million in 2024, then jumped by 776.23% to $1.1 billion in 2025, then retreated by 19.46% to $861.0 million in 2026.
• The last three Change in Accured Expenses figures came in at $861.0 million (Q1 2026), $1.1 billion (Q4 2025), and $602.0 million (Q3 2025), per Business Quant data.